Clinical Trial Update: A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

A randomized Phase II trial evaluating optimization of immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Squamous Cell Carcinoma of the Head and Neck

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Status: COMPLETED